Literature DB >> 15914558

Effect of transcription-factor concentrations on leukemic stem cells.

Frank Rosenbauer1, Steffen Koschmieder, Ulrich Steidl, Daniel G Tenen.   

Abstract

Increasing evidence suggests that leukemias are sustained by leukemic stem cells. However, the molecular pathways underlying the transformation of normal cells into leukemic stem cells are still poorly understood. The involvement of a small group of key transcription factors into this process was suggested by their frequent mutation or down-regulation in patients with acute myeloid leukemia (AML). Recent findings in mice with hypomorphic transcription-factor genes demonstrated that leukemic stem-cell formation in AML could directly be caused by reduced transcription-factor activity beyond a critical threshold. Most interestingly, those experimental models and the paucity of biallelic null mutations or deletions in transcription-factor genes in patients suggest that AML is generally associated with graded down-regulation rather than complete disruption of transcription factors. Here, we discuss the effects of transcription-factor concentrations on hematopoiesis and leukemia, with a focus on the regulation of transcription-factor gene expression as a major mechanism that alters critical threshold levels during blood development and cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914558      PMCID: PMC1895222          DOI: 10.1182/blood-2005-02-0717

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  76 in total

1.  Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors.

Authors:  Antonio Cozzio; Emmanuelle Passegué; Paul M Ayton; Holger Karsunky; Michael L Cleary; Irving L Weissman
Journal:  Genes Dev       Date:  2003-12-15       Impact factor: 11.361

2.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

Authors:  Catriona H M Jamieson; Laurie E Ailles; Scott J Dylla; Manja Muijtjens; Carol Jones; James L Zehnder; Jason Gotlib; Kevin Li; Markus G Manz; Armand Keating; Charles L Sawyers; Irving L Weissman
Journal:  N Engl J Med       Date:  2004-08-12       Impact factor: 91.245

3.  The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1.

Authors:  Berthold Göttgens; Cyril Broccardo; Maria-Jose Sanchez; Sophie Deveaux; George Murphy; Joachim R Göthert; Ekaterini Kotsopoulou; Sarah Kinston; Liz Delaney; Sandie Piltz; Linda M Barton; Kathy Knezevic; Wendy N Erber; C Glenn Begley; Jonathan Frampton; Anthony R Green
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

4.  Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells.

Authors:  N Rekhtman; F Radparvar; T Evans; A I Skoultchi
Journal:  Genes Dev       Date:  1999-06-01       Impact factor: 11.361

5.  Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1.

Authors:  P Zhang; G Behre; J Pan; A Iwama; N Wara-Aswapati; H S Radomska; P E Auron; D G Tenen; Z Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

6.  Leukemogenesis caused by incapacitated GATA-1 function.

Authors:  Ritsuko Shimizu; Takashi Kuroha; Osamu Ohneda; Xiaoqing Pan; Kinuko Ohneda; Satoru Takahashi; Sjaak Philipsen; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 7.  Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.

Authors:  Sandeep Gurbuxani; Paresh Vyas; John D Crispino
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

8.  Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.

Authors:  Kristin J Hope; Liqing Jin; John E Dick
Journal:  Nat Immunol       Date:  2004-05-30       Impact factor: 25.606

9.  PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain.

Authors:  Wendy D Cook; Benjamin J McCaw; Christopher Herring; Deborah L John; Simon J Foote; Stephen L Nutt; Jerry M Adams
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

10.  An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors.

Authors:  M Sánchez; B Göttgens; A M Sinclair; M Stanley; C G Begley; S Hunter; A R Green
Journal:  Development       Date:  1999-09       Impact factor: 6.868

View more
  38 in total

1.  Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.

Authors:  Laura Barreyro; Britta Will; Boris Bartholdy; Li Zhou; Tihomira I Todorova; Robert F Stanley; Susana Ben-Neriah; Cristina Montagna; Samir Parekh; Andrea Pellagatti; Jacqueline Boultwood; Elisabeth Paietta; Rhett P Ketterling; Larry Cripe; Hugo F Fernandez; Peter L Greenberg; Martin S Tallman; Christian Steidl; Constantine S Mitsiades; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

2.  CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.

Authors:  Steffen Koschmieder; Francesco D'Alò; Hanna Radomska; Christine Schöneich; Ji Suk Chang; Marina Konopleva; Susumu Kobayashi; Elena Levantini; Nanjoo Suh; Annalisa Di Ruscio; Maria Teresa Voso; Julie C Watt; Ramasamy Santhanam; Bülent Sargin; Hagop Kantarjian; Michael Andreeff; Michael B Sporn; Danilo Perrotti; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve; Daniel G Tenen
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

3.  Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia.

Authors:  Donald Metcalf; Aleksandar Dakic; Sandra Mifsud; Ladina Di Rago; Li Wu; Stephen Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

4.  The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation.

Authors:  A Rosa; M Ballarino; A Sorrentino; O Sthandier; F G De Angelis; M Marchioni; B Masella; A Guarini; A Fatica; C Peschle; I Bozzoni
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

Review 5.  A STATus report on DC development.

Authors:  Haiyan S Li; Stephanie S Watowich
Journal:  J Leukoc Biol       Date:  2012-05-01       Impact factor: 4.962

6.  The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development.

Authors:  Haiyan S Li; Cliff Y Yang; Kalyan C Nallaparaju; Huiyuan Zhang; Yong-Jun Liu; Ananda W Goldrath; Stephanie S Watowich
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

7.  The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation.

Authors:  Mark W Feinberg; Akm Khyrul Wara; Zhuoxiao Cao; Maria A Lebedeva; Frank Rosenbauer; Hiromi Iwasaki; Hideyo Hirai; Jonathan P Katz; Richard L Haspel; Susan Gray; Koichi Akashi; Julie Segre; Klaus H Kaestner; Daniel G Tenen; Mukesh K Jain
Journal:  EMBO J       Date:  2007-08-30       Impact factor: 11.598

8.  Novel role for EKLF in megakaryocyte lineage commitment.

Authors:  Pilar Frontelo; Deepa Manwani; Mariann Galdass; Holger Karsunky; Felix Lohmann; Patrick G Gallagher; James J Bieker
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

Review 9.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

10.  Importance of receptor usage, Fli1 activation, and mouse strain for the stem cell specificity of 10A1 murine leukemia virus leukemogenicity.

Authors:  Michaela Rodenburg; Meike Fischer; Afra Engelmann; Stephanie O Harbers; Marion Ziegler; Jürgen Löhler; Carol Stocking
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.